Recurrent Childhood Soft Tissue Sarcoma Recruiting Phase 2 Trials for Cabozantinib (DB08875)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02867592Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsTreatment